Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Debt (2017 - 2023)

Sutro Biopharma (STRO) has disclosed Total Debt for 7 consecutive years, with $4.1 million as the latest value for Q4 2023.

  • Quarterly Total Debt fell 75.04% to $4.1 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was $4.1 million through Dec 2023, down 75.04% year-over-year, with the annual reading at $4.1 million for FY2023, 75.04% down from the prior year.
  • Total Debt hit $4.1 million in Q4 2023 for Sutro Biopharma, down from $7.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $25.3 million in Q1 2022 to a low of $4.1 million in Q4 2023.
  • Historically, Total Debt has averaged $18.1 million across 5 years, with a median of $20.8 million in 2022.
  • Biggest five-year swings in Total Debt: soared 148.53% in 2020 and later crashed 75.04% in 2023.
  • Year by year, Total Debt stood at $9.9 million in 2019, then skyrocketed by 148.53% to $24.5 million in 2020, then rose by 2.31% to $25.1 million in 2021, then crashed by 35.21% to $16.3 million in 2022, then plummeted by 75.04% to $4.1 million in 2023.
  • Business Quant data shows Total Debt for STRO at $4.1 million in Q4 2023, $7.1 million in Q3 2023, and $10.2 million in Q2 2023.